Skip to main content

Table 3 Cost-effectiveness, Sensitivity Analysis

From: Cost-effectiveness and budget impact of the management of uncomplicated urinary tract infection by community pharmacists

Strategy Mean Costs, $ Mean Effects, QALMs Incremental Costs, $ Incremental Effects, QALMs ICER, $/QALM gained
Cure rate of community pharmacist-initiated antibiotic-treatment (86%)
Community pharmacist-initiated 72.81 (49.77; 99.77) 0.75229 (0.51536; 0.92437)
Family physician-initiated 142.01 (95.73; 197.40) 0.75233 (0.51488; 0.92407) 69.20 (15.50; 129.40) 0.00004 (−0.00726; 0.00698) 1,730,000
Emergency physician-initiated 371.09 (232.14; 546.54) 0.75237 (0.51973; 0.92503) Extended dominance
Cure rate of community pharmacist-initiated antibiotic-treatment (83%)
Community pharmacist-initiated 72.90 (50.07; 100.88) 0.75326 (0.52212; 0.92515)
Family physician-initiated 141.74 (94.71; 197.46) 0.75328 (0.52284; 0.92450) 68.85 (14.61; 129.57) 0.00002 (−0.00714; 0.00701) 3,442,500
Emergency physician-initiated 370.36 (229.47; 546.86) 0.75333 (0.52349; 0.92436) Extended dominance
  1. Sequential analysis